-
FDA approves BAVENCIO in association with axiathani as a first-line treatment for patients with advanced renal cell carcinoma (RCC)
Time of Update: 2020-06-09
recently, the United States The FDA (http:// approved BAVENCIO (Avelumab) in conjunction with INLYTA as a first-line treatment for patients with advanced renal cell carcinoma (RCC) this is also
-
FDA approves Ppelisib to work with Fulvestrant to treat breast cancer patients
Time of Update: 2020-06-09
recently, the United States The FDA (http:// approve disapprove of the Piqray pill, in conjunction with the Endocrine Therapy Drug (http:// Fulvestrant, to treat patients with premenopausal wo
-
FDA grants Keytruda and Lenvima combination therapy to treat patients with advanced, non-reprectoable hepatocellular carcinoma
Time of Update: 2020-06-09
today, MSD and Eisai jointly announced that the u.S FDA (http:// has awarded Keytruda and Lenvima breakthrough therapies for advanced, non-reprecentable patients with advanced, non-reprecision in
-
Israel's Vaxival Bios develops cancer vaccine "ImMucin" to stop cancer recurrence
Time of Update: 2020-06-09
Recent lying news emerged that http:// an Israeli biotech company, had developed a revolutionary cancer vaccine, ImMucin, Vaxil Bios, specifically designed to prevent a recurrence after cancer tre
-
EU grants Libtayo ® (cemiplimab) listing license for treatment of CSCC adult patients
Time of Update: 2020-06-09
recently, Sanofi and Regeneration announced that the European Union has granted Libtayo ® a conditional listing license for the treatment of adult patients with metastatic or localized advanced skin
-
Tamabian Mitsubishi submits Application for New Drug for Vadadustat to Japan's Ministry of Health, Labour and Welfare
Time of Update: 2020-06-09
Recently, Akebia Therapeutics announced that its partner, Mitsubishi Tanaka, has submitted Vadadustat's New Drug (http:// Listing Application (JNDA) to Japan's Ministry of Health, Labour and Welf
-
FDA approves Botulinum Toxin A, BOTOX to expand indications
Time of Update: 2020-06-09
recently, Allergan announced that it The FDA (http:// approved its Botulinum Toxin A,BOTOX expansion algelisted indications to treat upper limb spasms in children (2 to 17 years old) in addition
-
MHLW approves first three-year oral FLT3 inhibitor Vanflytinib to be launched
Time of Update: 2020-06-09
AML is a rapidly developing blood and bone marrow cancer, and cancerous white blood cells in patients are growing rapidly, not only do they fail to function normally, but also affect the production
-
FDA approves Pfizer Ruxience for adult patients to treat a wide range of diseases
Time of Update: 2020-06-09
recently, Pfizer announced that the U.S Food and Drug (http:// Administration ( FDA (http:// ) has approved Ruxience (rituximab-pvvr, ritusxixipro, rituxixixim) for the treatment of adult patie
-
CHMP recommends approval of Alexion's ultomiris (ravulizumab) for the treatment of haemoglobinuria
Time of Update: 2020-06-09
recently, Alexion (http:// announced that the European medicines (http:// Authority ( HTTP://WWW.CHEMDRUG.COM/) Product http:// sons and http:// (http:// Committee (CHMP) has issued an act
-
Novo Nordisk releases data on ElLipsE, Phase III clinical study of Victoza (liraglutide, liraglutide)
Time of Update: 2020-06-09
recently, diabetes giant Novo Nordisk released data from elLipsE, a phase III clinical study of Victoza The study, the first Phase III study to be completed in the past 10 years in a group of chil
-
FDA approves Belimumab intravenous infusion for children under 5 years of age with systemic lupus
Time of Update: 2020-06-09
systemic lupus erythematosus (SLE), commonly referred to simply as lupus, is a serious chronic disease that causes inflammation and various body damage to tissues and organs Recently, the FDA (ht
-
FDA accepts new drug application from Melinta's Baxdela
Time of Update: 2020-06-09
CABP is pneumonia that is infected outside the Medical (http:// facility The most common pathogens are streptococcus pneumoniae, haemophilus influenzae type flue goecole and atypical bacteria (e.
-
Health Canada approves new kiPomalyste with Velcade and dexamethasone for treatment of adult patients with myeloma
Time of Update: 2020-06-09
recently announced that Health Canada has approved Pomalyste (pomalidomide, Pomadomide) and Velcade (bortezomib, bortezomib) and dexamethasone three-drug program (PVd) for adults who have previously
-
FDA accepts new drug application for zejula, an oral PARP inhibitor, submitted by glaxoSmithKline
Time of Update: 2020-06-09
recently, GlaxoSmithKline (GSK) announced that the Us The FDA (http:// has accepted its submitted supplementtoly new drug (http:// application (http:// and will review it as a priority for PDU
-
Phase 3 clinical trial of VIIV antiviral therapy fostemsavir for HIV-1 adult patients achieves positive results
Time of Update: 2020-06-09
today, The http:// a company dedicated to developing innovative HIV , announced that its "first-in-class" antiviral therapy, fostemsavir, has achieved positive results in the of phase 3 clinical
-
The European Commission has approved Portola's Andexxya for anticoagulant in the event of life-threatening or uncontrolled bleeding
Time of Update: 2020-06-09
recently, Portola (http:// announced that the European Commission (EC) had the conditions to approve Andexxya (andexanet alfa) for anticoagulant reversal spawning in the event of life-threatening
-
Pfizer Vizimpro (dacomitinib) recommended by UK regulators to treat NSCLC
Time of Update: 2020-06-09
recentdays, Pfizer's Vizimpro (dacomitinib) has been recommended by regulators in the UK as a first-line treatment option for patients with late-stage or metastatic non-small cell lung cancer (NSCLC
-
FDA approves U.S. FDA-approved midazolam nasal spray for cluster seizures over 12 years of age
Time of Update: 2020-06-09
epilepsy is a chronic neurological disease in the brain It is the world's fourth-largest neurological disease, affecting the lives of about 65 million people It is estimated that 150,000 people with
-
FDA approves Darzalex (Daratumumab) combination drug to treat multiple myeloma patients
Time of Update: 2020-06-09
multiple myeloma is a malignant blood cancer caused by plasma cell cancer in the bone marrow today, johnson-owned janson (http:// announced that the U.S FDA (http:// approved the company's jo
